Effects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE) A Randomized Trial Protocol

Simple item page
dc.catalogadordfo
dc.contributor.authorMartínez, Felipe
dc.contributor.authorTaramasco Toro, Carla
dc.contributor.authorEspinoza Sepúlveda, Manuel Antonio
dc.contributor.authorAcevedo, Johanna
dc.contributor.authorGoic Boroevic, Carolina
dc.contributor.authorNervi Nattero, Bruno
dc.date.accessioned2024-03-27T13:31:57Z
dc.date.available2024-03-27T13:31:57Z
dc.date.issued2024
dc.description.abstractCancer, a pervasive global health challenge, necessitates chemotherapy or radiotherapy treatments for many prevalent forms. However, traditional follow-up approaches encounter limitations, exacerbated by the recent COVID-19 pandemic. Consequently, telemonitoring has emerged as a promising solution, although its clinical implementation lacks comprehensive evidence. This report depicts the methodology of a randomized trial which aims to investigate whether leveraging a smartphone app called Contigo for disease monitoring enhances self-reported quality of life among patients with various solid cancers compared to standard care. Secondary objectives encompass evaluating the app’s impact on depressive symptoms and assessing adherence to in-person appointments. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients’ progress and providing educational content to assist patients in managing common clinical situations related to their disease. The study will assess outcomes such as quality of life changes and depressive symptom development using validated scales, and adherence to in-person appointments. Specific scales include the EuroQol Group’s EQ-5D questionnaire and the Patient Health Questionnaire (PHQ-9). We hypothesize that the use of Contigo will assist and empower patients receiving cancer treatment, which will translate to better quality of life scores and a reduced incidence of depressive symptoms. All analyses will be undertaken with the intention-to-treat principle by a statistician unaware of treatment allocation. This trial is registered in ClinicalTrials under the registration number NCT06086990
dc.fechaingreso.objetodigital2024-03-27
dc.fuente.origenORCID
dc.identifier.doi10.3390/mps7020024
dc.identifier.eissn2409-9279
dc.identifier.urihttps://doi.org/10.3390/mps7020024
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84703
dc.identifier.urihttps://www.mdpi.com/2409-9279/7/2/24
dc.information.autorucEscuela de Medicina; Nervi Nattero, Bruno; 0000-0002-3016-7261; 604
dc.information.autorucEscuela de Medicina; Espinoza Sepulveda Manuel Antonio; 0000-0001-9564-9512; 10720
dc.information.autorucEscuela de Medicina; Goic Boroevic Carolina; S/I; 67870
dc.information.autorucEscuela de Medicina; Nervi Nattero Bruno; 0000-0002-3016-7261; 604
dc.issue.numero2
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final10
dc.pagina.inicio1
dc.revistaMethods and protocols
dc.rightsacceso abierto
dc.rights.licenseAttribution 4.0 International (CC BY 4.0)
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCancer
dc.subjectOncology
dc.subjectTelemonitoring
dc.subjectPatient surveillance
dc.subjectInternet
dc.subjectSmartphone
dc.subjectQuality of life
dc.subjectToxicity
dc.subjectAdverse events
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleEffects on Quality of Life of a Telemonitoring Platform amongst Patients with Cancer (EQUALITE) A Randomized Trial Protocol
dc.typeartículo
dc.volumen7
sipa.codpersvinculados604
sipa.codpersvinculados10720
sipa.codpersvinculados67870
sipa.trazabilidadORCID;2024-03-25
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mps-07-00024.pdf
Size:
942.02 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas